Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP

Business Wire05-02

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers WILMINGTON, Mass., May 02, 2024--(BUSINESS WIRE)--Charles River Laboratories ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432677687?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UQGjqAddApmBpz_jsGKe2g--~B/aD0zMjY7dz0xMjQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f0c3e20e1c8ea582ad37f70d0d64b610","is_english":true,"pubTime":"2024-05-02 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2432677687","market":"us","top_or_hot":-1,"title":"Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP","media":"Business Wire","content":"<div>\n<p>Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers\nWILMINGTON, Mass., May 02, 2024--(BUSINESS WIRE)--Charles River Laboratories ...</p>\n\n<a href=\"https://finance.yahoo.com/news/charles-river-launches-viral-vector-120000950.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-02 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/charles-river-launches-viral-vector-120000950.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers\nWILMINGTON, Mass., May 02, 2024--(BUSINESS WIRE)--Charles River Laboratories ...</p>\n\n<a href=\"https://finance.yahoo.com/news/charles-river-launches-viral-vector-120000950.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://finance.yahoo.com/news/charles-river-launches-viral-vector-120000950.html","article_id":"2432677687","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UQGjqAddApmBpz_jsGKe2g--~B/aD0zMjY7dz0xMjQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f0c3e20e1c8ea582ad37f70d0d64b610"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432677687","pubTimestamp":1714651200,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration , plus five LVV reference material products, available with different combinations of promoters and reporter genes. The additional reference materials add to the Company’s extensive portfolio of plasmid and viral vector contract development and manufacturing organization  offerings, reinforcing its concept-to-cure commitment to CGT researchers and developers by enabling partners to navigate the path from early discovery to commercial.ASGCT LaunchCharles River will officially launch its AAV and LVV reference materials with supporting case study data during the American Society of Gene and Cell Therapy  Annual Meeting, May 7 – 11, 2024, in Baltimore, MD.Cell and Gene ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","ARKG":"ARK Genomic Revolution ETF","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","BK4075":"烟草","CDMO":"Avid Bioservices, Inc.","BK4561":"索罗斯持仓","BK4139":"生物科技","BK4530":"医药外包概念","CRL":"查尔斯河","BK4121":"生命科学工具和服务","VAQC":"Vector Acquisition Corporation II","BK4585":"ETF&股票定投概念","VGR":"Vector Group Ltd."},"translate_title":"Charles River推出病毒载体参考材料以简化向GMP的过渡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARKG":1,"CDMO":1,"VAQC":1,"VGR":1,"CRL":0.9},"content_text":"Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers\nWILMINGTON, Mass., May 02, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.\nMoving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration (GC/mL), plus five LVV reference material products, available with different combinations of promoters and reporter genes. The additional reference materials add to the Company’s extensive portfolio of plasmid and viral vector contract development and manufacturing organization (CDMO) offerings, reinforcing its concept-to-cure commitment to CGT researchers and developers by enabling partners to navigate the path from early discovery to commercial.\nASGCT LaunchCharles River will officially launch its AAV and LVV reference materials with supporting case study data during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 7 – 11, 2024, in Baltimore, MD.\nMeet the Charles River team at Booth #327 to discuss how to streamline the CGT research and development process, and explore various presentations and scientific posters from subject matter experts, including:\n\nA cross-functional research and discovery project showcasing AAV reference material data, AAV Cell Surface Target Profiling Using Binding and Functional Cell Microarray Screening Technology (#462), presented by Claire Tebbutt, Group Leader, Discovery\n  \nWednesday, May 8, 12:00-7:00 p.m.: AAV Vectors – Virology and Vectorology (Exhibit Hall)\n\nClosed Automation Enables Quick Fill-Finish of Large-Scale T Cell Therapy While Maintaining Consistency and Quality of the Final Product (#867), presented by Min Sung Park, Process Development Scientist, Cell and Gene Therapy CDMO Services\n  \nWednesday, May 8, 12:00-7:00 p.m.: Cell Therapy Product Engineering, Development, and Manufacturing (Exhibit Hall)\n\nMatrix Approach for Potency Assay Development of Cell and Gene Therapy Products: A Case Study for AAV Vectors (#1519), presented by Karen Doucette, Scientific Advisor, Cell and Gene Therapy CDMO Services\n  \nFriday, May 10, 12:00-7:00 p.m.: AAV Vectors - Product Development Manufacturing and Approval Considerations (Exhibit Hall)\n\n\nTo view the full list and to schedule a meeting, visit criver.com.\nCell and Gene Therapy CDMO SolutionsWith a strong track record supporting multiple client programs, Charles River’s viral vector CDMO center of excellence in Rockville, MD, offers integrated solutions to support CGT programs from pre-clinical research to commercial scale.\nTo learn more about Charles River’s CGT portfolio and gain real-world insights from a development, manufacturing, and testing perspective, join an expert roundtable webinar hosted by Human Gene Therapy, Streamlining Cell and Gene Therapy Scalability: Progress Towards a Gold Standard, moderated by James Cody, PhD, Associate Director, Technical Evaluations on May 13, 2024.\nTo learn more about optimizing the development of gene therapy products, join the upcoming Charles River webinar, The Roadmap to Fast-Tracking Gene Therapy Development, on June 4, 2024. The multi-disciplinary panel will explore in vitro approaches to optimize and support the development of gene therapy products, including key considerations and real-world data highlighting routes to de-risk your therapeutic product.\nApproved Quotes\n\n\"This expansion of the CGT product portfolio empowers our partners to navigate the path from research to commercialization under one organization, providing a streamlined process. Combined with Charles River’s established CDMO capabilities, this enables us to continue to work towards our ultimate goal of delivering safe, effective therapies to patients faster.\" – Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River\n\"The launch of Charles River’s AAV and LVV reference materials portfolio is the latest in a series of enhancements in our CDMO products and services offerings. We look forward to showcasing our robust portfolio and supporting data during the ASGCT Annual Meeting.\" – Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, Charles River\n\nAbout Charles RiverCharles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240502084745/en/\nContacts\nInvestor Contact: Todd SpencerCorporate Vice President,Investor Relations781.222.6455todd.spencer@crl.com\nMedia Contact: Amy CianciarusoCorporate Vice President,Chief Communications Officer781.222.6168amy.cianciaruso@crl.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432677687"}